Growth Metrics

NovoCure (NVCR) Cost of Revenue (2016 - 2026)

NovoCure's Cost of Revenue history spans 13 years, with the latest figure at $38.9 million for Q1 2026.

  • On a quarterly basis, Cost of Revenue rose 1.06% to $38.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $150.0 million, a 102.52% increase, with the full-year FY2025 number at $166.9 million, up 21.65% from a year prior.
  • Cost of Revenue hit $38.9 million in Q1 2026 for NovoCure, up from -$4.5 million in the prior quarter.
  • Over the last five years, Cost of Revenue for NVCR hit a ceiling of $58.5 million in Q3 2025 and a floor of -$39.3 million in Q4 2023.
  • Historically, Cost of Revenue has averaged $25.9 million across 5 years, with a median of $33.7 million in 2024.
  • Biggest five-year swings in Cost of Revenue: tumbled 236.18% in 2023 and later surged 86.87% in 2025.
  • Tracing NVCR's Cost of Revenue over 5 years: stood at $28.9 million in 2022, then tumbled by 236.18% to -$39.3 million in 2023, then increased by 12.38% to -$34.5 million in 2024, then surged by 86.87% to -$4.5 million in 2025, then skyrocketed by 960.31% to $38.9 million in 2026.
  • Business Quant data shows Cost of Revenue for NVCR at $38.9 million in Q1 2026, -$4.5 million in Q4 2025, and $58.5 million in Q3 2025.